Fig. 1.

Upregulation of ACSL3 mRNA expression by synthetic LXR agonists in primary human trophoblasts and BeWo cells. A: Primary trophoblasts were incubated in triplicate with vehicle (white bars) or T0901317 (1 μM, black bars) for 24 h in three independent placenta isolations. B: BeWo cells were incubated with vehicle (white bars), 9-cis RA (1 μM, gray bars), T0901317 (1 μM, bars with small dots), both agonists (bars with big dots), GW3965 (1 μM, striped bars), or GW3965 and 9-cis RA together (black bars) for 48 h. ACSL3 and SREBP-1 expression were analyzed by qRT-PCR and normalized to TBP. Each experiment was performed in triplicate. Data shown represents the means of three independent experiments performed in triplicate (n = 3) ± SEM, relative to control. *P < 0.05 and **P < 0.01 relative to control. ACSL, long-chain acyl-CoA synthetase; BeWo, human placental choriocarcinoma; LXR, liver X receptor; qRT-PCR, quantitative reverse transcription-PCR; SREBP-1, sterol-regulatory element binding protein-1; TBP, TATA box binding protein.